Outcomes of As-Needed Aflibercept Treatment After Complete Regression in Polypoidal Choroidal Vasculopathy: A Clinical Review
Highlights
- Approximately half of PCV eyes with complete polypoidal regression under aflibercept experience recurrence within 2 years when managed with PRN regimens.
- Visual acuity decline and new hemorrhages occur in a subset of recurrent cases, underscoring the need for vigilant monitoring.
- Baseline presence of massive subretinal hemorrhage may predict lower recurrence risk, while leakage without hemorrhage may indicate higher recurrence potential.
- Posttreatment OCT biomarkers offer promising stratification tools for tailoring continuation versus deferral of anti-VEGF therapy in PCV.
Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.